Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) was up 10.5% during mid-day trading on Monday . The company traded as high as $2.35 and last traded at $2.10, with a volume of 3,167,164 shares changing hands. The stock had previously closed at $1.90.

A number of equities research analysts recently issued reports on CNAT shares. Roth Capital started coverage on shares of Conatus Pharmaceuticals in a report on Friday, July 1st. They issued a “buy” rating for the company. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Wednesday, August 10th. Brean Capital set a $7.00 target price on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Sunday, May 8th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $9.41.

The firm’s market capitalization is $44.14 million. The company’s 50-day moving average is $2.11 and its 200-day moving average is $2.22.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.08. During the same period last year, the company posted ($0.31) EPS. On average, equities research analysts expect that Conatus Pharmaceuticals Inc. will post ($1.34) EPS for the current year.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.